How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent growth trend in net sales and profits over the past four years, culminating in the fiscal year ending March 2025.

Breakdown:
Concord Biotech's net sales increased from 712.93 Cr in March 2022 to 1,200.09 Cr in March 2025, reflecting a strong upward trajectory. Total operating income followed a similar pattern, rising from 712.93 Cr in March 2022 to 1,200.09 Cr in March 2025. The total expenditure, excluding depreciation, also grew, reaching 693.76 Cr in March 2025, up from 439.66 Cr in March 2022. Operating profit (PBDIT) saw a significant increase from 296.69 Cr in March 2022 to 550.78 Cr in March 2025, indicating improved operational efficiency. Profit before tax rose from 241.16 Cr in March 2022 to 495.87 Cr in March 2025, while profit after tax increased from 178.57 Cr to 372.96 Cr during the same period. The earnings per share (EPS) also improved from 16.72 in March 2022 to 35.53 in March 2025. On the balance sheet, total assets grew from 1,312.79 Cr in March 2022 to 2,034.25 Cr in March 2025, while total liabilities increased from 1,312.79 Cr to 2,034.25 Cr, reflecting the company's expanding operations. Cash flow from operating activities showed a slight decline from 265.00 Cr in March 2024 to 244.00 Cr in March 2025, with a net cash outflow of 14.00 Cr in March 2025. Overall, Concord Biotech has demonstrated robust growth in revenue and profitability, alongside a solid asset base.